Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Cyclophosphamide Followed by Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis
NCT00939549Phase 2Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Nov 2010
- Primary completion
- Nov 2010
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and glatiramer acetate in multiple sclerosis (MS), sponsored by Johns Hopkins University. Primary endpoint: Serious adverse events at 2 years. Planned start Nov 2010; status: withdrawn.
02
Drugs
cyclophosphamideglatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00939549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00939549.